Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells.
Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, Blaser BW, Huszar D, Helmig-Mason J, Zhang L, Schrock MS, Summers MK, Chan WK, Prouty A, Mundy-Bosse BL, Chen-Kiang S, Danilov AV, Maddocks K, Baiocchi RA, Alinari L. Hanel W, et al. Among authors: sehgal l. Exp Hematol Oncol. 2022 Jul 13;11(1):40. doi: 10.1186/s40164-022-00293-y. Exp Hematol Oncol. 2022. PMID: 35831896 Free PMC article.
Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowdhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L. Jain N, et al. Among authors: sehgal l. Blood Adv. 2020 Sep 22;4(18):4382-4392. doi: 10.1182/bloodadvances.2020001685. Blood Adv. 2020. PMID: 32926124 Free PMC article.
Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma.
Choueiry F, Singh S, Sircar A, Laliotis G, Sun X, Chavdoula E, Zhang S, Helmig-Mason J, Hart A, Epperla N, Tsichlis P, Baiocchi R, Alinari L, Zhu J, Sehgal L. Choueiry F, et al. Among authors: sehgal l. Cancers (Basel). 2021 Apr 29;13(9):2146. doi: 10.3390/cancers13092146. Cancers (Basel). 2021. PMID: 33946867 Free PMC article.
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L. Sloan SL, et al. Among authors: sehgal l. Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419. Blood. 2023. PMID: 37267517
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma.
Brown-Burke F, Hwang I, Sloan S, Hinterschied C, Helmig-Mason J, Long M, Chan WK, Prouty A, Chung JH, Zhang Y, Singh S, Youssef Y, Bhagwat N, Chen Z, Chen-Kiang S, Di Liberto M, Elemento O, Sehgal L, Alinari L, Vaddi K, Scherle P, Lapalombella R, Paik J, Baiocchi RA. Brown-Burke F, et al. Among authors: sehgal l. Blood Adv. 2023 Oct 24;7(20):6211-6224. doi: 10.1182/bloodadvances.2023009906. Blood Adv. 2023. PMID: 37327122 Free PMC article.
Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, Ranganathan P, Jain N, Hanel W, Tsichlis P, Alinari L, Peterson BR, Tao J, Muthusamy N, Baiocchi R, Epperla N, Young KH, Morin R, Sehgal L. Sircar A, et al. Among authors: sehgal l. Leukemia. 2023 Oct;37(10):2094-2106. doi: 10.1038/s41375-023-02006-8. Epub 2023 Aug 19. Leukemia. 2023. PMID: 37598282 Free PMC article.
Targeting Wnt pathway in mantle cell lymphoma-initiating cells.
Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Mathur R, et al. Among authors: sehgal l. J Hematol Oncol. 2015 Jun 6;8:63. doi: 10.1186/s13045-015-0161-1. J Hematol Oncol. 2015. PMID: 26048374 Free PMC article.
Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease.
Snyder KJ, Choe HK, Gao Y, Sell NE, Braunreiter KM, Zitzer NC, Neidemire-Colley L, Kalyan S, Dorrance AM, Keller A, Mihaylova MM, Singh S, Sehgal L, Bollag G, Ma Y, Powell B, Devine SM, Ranganathan P. Snyder KJ, et al. Among authors: sehgal l. Front Oncol. 2021 Oct 15;11:760789. doi: 10.3389/fonc.2021.760789. eCollection 2021. Front Oncol. 2021. PMID: 34722316 Free PMC article.
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Zhao X, Wang MY, Jiang H, Lwin T, Park PM, Gao J, Meads MB, Ren Y, Li T, Sun J, Fahmi NA, Singh S, Sehgal L, Wang X, Silva AS, Sotomayor EM, Shain KH, Cleveland JL, Wang M, Zhang W, Qi J, Shah BD, Tao J. Zhao X, et al. Among authors: sehgal l. Cell Rep. 2021 Mar 16;34(11):108870. doi: 10.1016/j.celrep.2021.108870. Cell Rep. 2021. PMID: 33730585 Free PMC article.
143 results